These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 30705085)

  • 21. Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers.
    Hyun S; Shin D
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS
    Mortier J; Friberg A; Badock V; Moosmayer D; Schroeder J; Steigemann P; Siegel F; Gradl S; Bauser M; Hillig RC; Briem H; Eis K; Bader B; Nguyen D; Christ CD
    ChemMedChem; 2020 May; 15(10):827-832. PubMed ID: 32237114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-throughput, single-particle tracking reveals nested membrane domains that dictate KRas
    Lee Y; Phelps C; Huang T; Mostofian B; Wu L; Zhang Y; Tao K; Chang YH; Stork PJ; Gray JW; Zuckerman DM; Nan X
    Elife; 2019 Nov; 8():. PubMed ID: 31674905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.
    Tang D; Kroemer G; Kang R
    Mol Cancer; 2021 Oct; 20(1):128. PubMed ID: 34607583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRAS: A Promising Therapeutic Target for Cancer Treatment.
    Wu HZ; Xiao JQ; Xiao SS; Cheng Y
    Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents.
    Li L; Zhao H; Liao H; Chen J; Liu J; Chen J
    Bioorg Chem; 2021 May; 110():104825. PubMed ID: 33774492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
    Nussinov R; Zhang M; Tsai CJ; Jang H
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
    Stites EC; Shaw AS
    CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting mutant KRAS.
    Erlanson DA; Webster KR
    Curr Opin Chem Biol; 2021 Jun; 62():101-108. PubMed ID: 33838397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drugging all RAS isoforms with one pocket.
    Kessler D; Bergner A; Böttcher J; Fischer G; Döbel S; Hinkel M; Müllauer B; Weiss-Puxbaum A; McConnell DB
    Future Med Chem; 2020 Nov; 12(21):1911-1923. PubMed ID: 32779487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics.
    Hamilton G; Plangger A
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1065-1074. PubMed ID: 34347509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Covalent inhibitors of the GTPase KRAS
    Kettle JG; Cassar DJ
    Expert Opin Ther Pat; 2020 Feb; 30(2):103-120. PubMed ID: 31913776
    [No Abstract]   [Full Text] [Related]  

  • 33. Improving Prospects for Targeting RAS.
    Singh H; Longo DL; Chabner BA
    J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRAS
    Ma X; Sloman DL; Duggal R; Anderson KD; Ballard JE; Bharathan I; Brynczka C; Gathiaka S; Henderson TJ; Lyons TW; Miller R; Munsell EV; Orth P; Otte RD; Palani A; Rankic DA; Robinson MR; Sather AC; Solban N; Song XS; Wen X; Xu Z; Yang Y; Yang R; Day PJ; Stoeck A; Bennett DJ; Han Y
    J Med Chem; 2024 Jul; 67(13):11024-11052. PubMed ID: 38924388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the undruggable oncogenic KRAS: the dawn of hope.
    Asimgil H; Ertetik U; Çevik NC; Ekizce M; Doğruöz A; Gökalp M; Arık-Sever E; Istvanffy R; Friess H; Ceyhan GO; Demir IE
    JCI Insight; 2022 Jan; 7(1):. PubMed ID: 35014625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
    Cox AD; Der CJ; Philips MR
    Clin Cancer Res; 2015 Apr; 21(8):1819-27. PubMed ID: 25878363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting Mutant KRAS for Anticancer Therapy.
    Chen F; Alphonse MP; Liu Y; Liu Q
    Curr Top Med Chem; 2019; 19(23):2098-2113. PubMed ID: 31475898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of the Clinical Development Candidate
    Fell JB; Fischer JP; Baer BR; Blake JF; Bouhana K; Briere DM; Brown KD; Burgess LE; Burns AC; Burkard MR; Chiang H; Chicarelli MJ; Cook AW; Gaudino JJ; Hallin J; Hanson L; Hartley DP; Hicken EJ; Hingorani GP; Hinklin RJ; Mejia MJ; Olson P; Otten JN; Rhodes SP; Rodriguez ME; Savechenkov P; Smith DJ; Sudhakar N; Sullivan FX; Tang TP; Vigers GP; Wollenberg L; Christensen JG; Marx MA
    J Med Chem; 2020 Jul; 63(13):6679-6693. PubMed ID: 32250617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.
    Hillig RC; Sautier B; Schroeder J; Moosmayer D; Hilpmann A; Stegmann CM; Werbeck ND; Briem H; Boemer U; Weiske J; Badock V; Mastouri J; Petersen K; Siemeister G; Kahmann JD; Wegener D; Böhnke N; Eis K; Graham K; Wortmann L; von Nussbaum F; Bader B
    Proc Natl Acad Sci U S A; 2019 Feb; 116(7):2551-2560. PubMed ID: 30683722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. K-Ras prenylation as a potential anticancer target.
    Baranyi M; Buday L; Hegedűs B
    Cancer Metastasis Rev; 2020 Dec; 39(4):1127-1141. PubMed ID: 32524209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.